COVID-19 Vaccine Update; Celecoxib Oral Solution OK'd for Migraine

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

3:03 AM (10 hours ago)

to me

If you are having trouble viewing this email, click here.

MUST READS COVID-19 mRNA Vaccine Candidates Advancing Through the Pipeline Celecoxib Oral Solution Approved for Acute Migraine Treatment Tabrecta Approved for METex14 Metastatic Non-Small Cell Lung Cancer Recarbrio Noninferior to Pip/Tazo for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia Microbiome-Based Therapy Looks Promising for Recurrent C. Difficile Infection COVID-19 Resource Center CME/CE Spotlight Navigating the Sleep-Wake Cycle: A Guided 3-D Animation AMA PRA Category 1 Credit(s)TM, CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME

COVID-19 mRNA Vaccine Candidates Advancing Through the Pipeline

MUST READS

COVID-19 mRNA Vaccine Candidates Advancing Through the Pipeline

Antihypertensives and COVID-19 Risk; New Heart Failure Treatment Approved

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

Thu, May 7, 3:07 AM (21 hours ago)

to me

If you are having trouble viewing this email, click here.

MUST READS Antihypertensive Medication Use Not Linked to Risk for COVID-19 Farxiga Approved for Heart Failure With Reduced Ejection Fraction Vadadustat Noninferior to Darbepoetin Alfa for Anemia in Patients With Dialysis-Dependent CKD Guidelines Issued for Managing Eosinophilic Esophagitis Inhaled Nitric Oxide Therapy Evaluated in Preterm Neonates With Pulmonary Hypertension COVID-19 Resource Center CME/CE Spotlight Improved Outcomes for Naïve & Heavily Treatment—Experienced HIV Patients AMA PRA Category 1 Credit(s)TM, CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME

New Drug Review: Tukysa

Inbox

x

MPR First Look <editor@email.empr.com> Unsubscribe

Wed, May 6, 7:05 PM (2 days ago)

to me

If you are having trouble viewing this email, click here.

NEW DRUG PRODUCT: TUKYSA FEATURED Find out more about Tukysa including dosing and important safety information with our slideshow, complete drug monograph, and downloadable PDF. DRUGS IN THE PIPELINE Dapagliflozin To Be Evaluated in COVID-19 Patients With Cardiovascular, Metabolic, or Renal Risk Factors Ultomiris to Be Evaluated for Severe COVID-19 in Phase 3 Trial Daridorexant Improves Sleep, Daytime Performance in Insomnia Study FDA to Review Data on Shorter Infusion Time for MS Drug Ocrevus Solution Stable Glucagon Granted Orphan Drug Status for Congenital Hyperinsulinism The right dose of information. eMPR.com CME/CE Spotlight Dispelling the Myths of Influenza Management AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s), CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME